KLUS Pharma is a clinical-stage biotech focusing on the discovery and development of novel and safer antibody-based therapeutics to treat cancer and other life-threatening diseases.
KLUS Pharma is the wholly-owned U.S. subsidiary of Kelun-Biotech, based in Cranbury, NJ. Kelun-Biotech is based in Chengdu, China.
We strive to discover and develop innovative biologics for the treatment of cancer and other serious diseases, addressing unmet needs and creating affordable medicines.
Our antibodies undergo affinity maturation, humanization, and Fc engineering, generating lead candidates with optimal efficacy and safety.
Our platform supports a wide variety of bispecific designs which allows for flexibility in selecting the optimal design based on intended MOA.